Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.41 |
| ▸ | PRCP | P42785 | 2/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30680482 | 0.98 | MEN1 (0.46) | MEN1KMT2ATERTSLC6A5CPB2 | |
| SCHEMBL20527740 | 0.89 | MEN1 (0.43) | MEN1KMT2ASLC6A5CPB2DPP7 | |
| SCHEMBL14906323 | 0.86 | MEN1 (0.48) | MEN1KMT2ACPB2FOLH1DPP7 | |
| SCHEMBL29578895 | 0.86 | MEN1 (0.48) | MEN1KMT2ACPB2FOLH1DPP7 | |
| SCHEMBL23303426 | 0.86 | MEN1 (0.48) | MEN1KMT2ACPB2FOLH1DPP7 | |
| SCHEMBL23303428 | 0.86 | MEN1 (0.48) | MEN1KMT2ACPB2FOLH1DPP7 | |
| SCHEMBL29470578 | 0.86 | MEN1 (0.48) | MEN1KMT2ACPB2FOLH1DPP7 | |
| SCHEMBL18075734 | 0.86 | MEN1 (0.48) | MEN1KMT2ACPB2FOLH1DPP7 | |
| SCHEMBL29824782 | 0.86 | NMT1 (0.40) | MEN1KMT2ATERTCPB2PRCP | |
| SCHEMBL30974373 | 0.86 | FOLH1 (0.44) | MEN1KMT2ATERTSLC6A5CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | MEN1 4441/4885KMT2A 357/4885TERT 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.